Bologna, Italy

Paolo Cantelmi

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Alma Mater Studiorum-Universitá Di Bologna, Fresenius Kabi Ipsum S.r.l.. Active years: 2023.


% Patents Active = 100.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Paolo Cantelmi: Innovator in Amino Deprotection Methods

Introduction

Paolo Cantelmi is a notable inventor based in Bologna, Italy. He has made significant contributions to the field of peptide synthesis, particularly through his innovative methods for amino deprotection. His work has implications for various applications in biochemistry and pharmaceuticals.

Latest Patents

Cantelmi holds a patent for a method titled "Amino deprotection using 3-(diethylamino)propylamine." This invention provides a method for the cleavage of the Fmoc group, characterized by using a solution comprising 3-(diethylamino)propylamine. Specifically, it offers a method for the preparation of peptides in solid phase, wherein Fmoc protected amino acids are utilized, and the Fmoc group is cleaved by a solution containing 3-(diethylamino)propylamine. He has 1 patent to his name.

Career Highlights

Throughout his career, Cantelmi has worked with prominent organizations, including Fresenius Kabi Ipsum S.r.l. and Alma Mater Studiorum-Università di Bologna. His experience in these institutions has allowed him to refine his expertise in peptide synthesis and related fields.

Collaborations

Cantelmi has collaborated with several professionals in his field, including Alessandra Tolomelli and Chiara Palladino. These collaborations have contributed to the advancement of his research and innovations.

Conclusion

Paolo Cantelmi is a distinguished inventor whose work in amino deprotection methods has made a significant impact in the field of peptide synthesis. His innovative approaches continue to influence research and applications in biochemistry and pharmaceuticals.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…